SECOND SIGHT MEDICAL PRODUCT (EYES) Stock Price, Quote, News and Overview
NASDAQ:EYES - Nasdaq - US81362J3086 - Common Stock - Currency: USD
EYES Quote, Performance and Key Statistics
4.14
-0.22 (-5.05%)
The current stock price of EYES is 4.14 USD. In the past month the price decreased by -23.33%. In the past year, price decreased by -63.1%.
EYES Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About EYES
Company Profile
Second Sight Medical Products Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Sylmar, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The firm manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). The company is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
Company Info
SECOND SIGHT MEDICAL PRODUCT
12744 San Fernando Road, Bldg. 3
Sylmar CALIFORNIA 91342 US
CEO: Matthew Pfeffer
Employees: 15
Company Website: http://www.secondsight.com/
Phone: 18188335000.0
SECOND SIGHT MEDICAL PRODUCT / EYES FAQ
What is the stock price of SECOND SIGHT MEDICAL PRODUCT today?
The current stock price of EYES is 4.14 USD. The price decreased by -5.05% in the last trading session.
What is the ticker symbol for SECOND SIGHT MEDICAL PRODUCT stock?
The exchange symbol of SECOND SIGHT MEDICAL PRODUCT is EYES and it is listed on the Nasdaq exchange.
On which exchange is EYES stock listed?
EYES stock is listed on the Nasdaq exchange.
What is SECOND SIGHT MEDICAL PRODUCT worth?
SECOND SIGHT MEDICAL PRODUCT (EYES) has a market capitalization of 54.38M USD. This makes EYES a Micro Cap stock.
How many employees does SECOND SIGHT MEDICAL PRODUCT have?
SECOND SIGHT MEDICAL PRODUCT (EYES) currently has 15 employees.
What are the support and resistance levels for SECOND SIGHT MEDICAL PRODUCT (EYES) stock?
SECOND SIGHT MEDICAL PRODUCT (EYES) has a support level at 4.14 and a resistance level at 7.53. Check the full technical report for a detailed analysis of EYES support and resistance levels.
Is SECOND SIGHT MEDICAL PRODUCT (EYES) expected to grow?
The Revenue of SECOND SIGHT MEDICAL PRODUCT (EYES) is expected to grow by 35.73% in the next year. Check the estimates tab for more information on the EYES EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SECOND SIGHT MEDICAL PRODUCT (EYES) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EYES, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EYES, evaluating the profitability, health, valuation and growth aspects
- SECOND SIGHT MEDICAL PRODUCT (EYES) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SECOND SIGHT MEDICAL PRODUCT (EYES) Sales and EPS estimates to see what analysts future expectations are.
- SECOND SIGHT MEDICAL PRODUCT (EYES) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SECOND SIGHT MEDICAL PRODUCT (EYES) Insider and Institutional Ownership to learn about the owners and their transactions.
- SECOND SIGHT MEDICAL PRODUCT (EYES) Stock Chart to make your own analysis
- SECOND SIGHT MEDICAL PRODUCT (EYES) Latest news and press-releases to stay up to date.
Does SECOND SIGHT MEDICAL PRODUCT (EYES) stock pay dividends?
EYES does not pay a dividend.
What is the Price/Earnings (PE) ratio of SECOND SIGHT MEDICAL PRODUCT (EYES)?
SECOND SIGHT MEDICAL PRODUCT (EYES) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
EYES Technical Analysis
EYES Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYES. While EYES has a great health rating, there are worries on its profitability.
EYES Financial Highlights
Over the last trailing twelve months EYES reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -42.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.82% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
EYES Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EYES. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 96.18% and a revenue growth 35.73% for EYES